PMV Pharmaceuticals Q3 2026 earnings

PMVP · 2026-11-10 08:00 BMO ET · 8-K on SEC · 10-Q on SEC

Net loss widened to $34.4 million due to non-cash warrant liability losses and offering costs, but cash position improved to $108.5 million following a $50 million public offering.

Headline numbers

MetricActualYoYQoQ8-K location
EPS (GAAP)-$0.52+30%—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $20.1 million (+12.2% YoY)
  • One-offs in the quarter Change in fair value of common stock warrant liability: -$12.8 million; Offering costs allocated to warrant liability: -$2.3 million
  • Effective tax rate 0% (prior-year 0%, year-to-date 0%)
  • Non-GAAP bridge No reconciliation provided; GAAP net loss includes non-cash warrant losses and offering costs.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents, and marketable securities$108.5 million$79.4 million$112.9 million+36.6% QoQ, -3.9% YoY
Net cash used in operations$52.4 million$34.3 million$56.4 million+52.5% QoQ, -7.1% YoY
Overall response rate (ORR)46%———

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported; company is clinical-stage with no product sales.
  • EPS story Net loss per share widened due to higher net loss and increased weighted-average shares outstanding.
  • One-off check Change in fair value of common stock warrant liability: -$12.8 million; Offering costs allocated to warrant liability: -$2.3 million.

The good

  • Cash position increased to $108.5 million following $50 million public offering
  • R&D expenses decreased year-over-year to $16.1 million
  • G&A expenses decreased year-over-year to $4.0 million
  • ORR of 46% in ovarian cancer cohort

The bad

  • Net loss widened to $34.4 million due to non-cash warrant losses and offering costs
  • Interest income decreased year-over-year to $830 thousand

The ugly

  • none

Open questions

  • Details on the specific fair value changes driving the warrant liability loss
  • Specifics on the offering costs allocation to the warrant liability
Full release

PMV Pharmaceuticals (PMVP) earnings release, November 10, 2026

PMV Pharmaceuticals, Inc. (PMVP) · Form 8-K, Item 2.02 · Filed · SEC filing

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights

• Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026

• Announced closing of oversubscribed $50 million public offering of securities

• Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027

• Cash, cash equivalents, and marketable securities of $108.5 million as of September 30, 2026 providing expected cash runway into first quarter of 2028

PRINCETON, N.J., November 10, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We achieved significant milestones during the third quarter across the organization,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a

TP53

Y220C mutation.”

Corporate Highlights

• Announced closing of oversubscribed $50 million public offering of securities (the “August 2026 Public Offering”), extending expected cash runway into first quarter of 2028.

• Provided PYNNACLE Phase 2 Monotherapy Update: o

Announced enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial has been completed. o

The Company plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts, including the primary analysis population data from the ovarian cancer cohort, in a late-breaking oral presentation at the 38 th

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). o

Announced updated rezatapopt monotherapy interim ovarian cancer data from PYNNACLE Phase 2 pivotal trial (May 14,

2026 cutoff date).

▪ The efficacy population consisted of 76 patients enrolled as of the data cutoff date who either had ≥1 post-baseline tumor assessment or discontinued early.

▪ Overall response rate (ORR) of 46% (35/76 patients, including four confirmed complete responses, 29 confirmed partial responses [PRs], and two unconfirmed PRs) per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

▪ The median time to response was 1.3 months and median duration of response was 10.0 months, based on confirmed responses only.

▪ Favorable and consistent safety and tolerability profile observed across all cohorts, with mostly Grade 1 and 2 treatment-related adverse events (AEs) observed as well as a low rate (5%) of discontinuation due to treatment-related AEs. The safety and tolerability profile of rezatapopt in the ovarian cancer cohort was similar to the overall population.

• Appointed Matt Eckler, Ph.D., of Samsara BioCapital to Board of Directors.

• Appointed Philip Herman as Chief Commercial Officer.

Third Quarter 2026 Financial Results

PMV Pharma ended the third quarter with $108.5 million in cash, cash equivalents, and marketable securities, compared to $112.9 million as of December 31, 2025. Net cash used in operations was $52.4 million for the nine months ended September 30, 2026, compared to $56.4 million for the nine months ended September 30, 2025.

• Net loss for the quarter ended September 30, 2026, was $34.4 million compared to $21.1 million for the quarter ended September 30, 2025. The net loss increase was primarily due to a $12.8 million non-cash loss from the change in fair value of the common stock warrant liability and $2.3 million of offering costs allocated to the warrant liability, both related to the August 2026 Public Offering, partially offset by decreased contract research organization costs.

• R&D expenses were $16.1 million for the quarter ended September 30, 2026, compared to $18.2 million for the quarter ended September 30, 2025. The decrease in R&D expenses was primarily due to decreased contract research organization costs for the advancement of the rezatapopt program.

• General and administrative (G&A) expenses were $4.0 million for the quarter ended September 30, 2026, compared to $4.3 million for the quarter ended September 30,

2025. The decrease in G&A expenses was primarily due to a decrease in finance and legal support costs, partially offset by increased personnel expenses.

About Rezatapopt

Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track Designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of

TP53

Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

About the PYNNACLE Clinical Trial

The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a

TP53... (truncated)ung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with

TP53

Y220C advanced solid tumors, conducted across approximately 70 sites.

For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53.

TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.

Financial statements

Income Statement

Three Months Ended September 30, — (in thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating expenses:
Research and development16,06318,21046,06954,050
General and administrative4,0004,31211,89412,914
Total operating expenses20,06322,52257,96366,964
Loss from operations-20,063-22,522-57,963-66,964
Other income (expense):
Interest income, net8301,4802,5985,105
Other expense, net-21-23-10-44
Change in fair value of warrant liability-12,781-12,781
Offering costs allocated to warrant liability-2,344-2,344
Total other (expense) income, net-14,3161,457-12,5375,061
Loss before benefit from income taxes-34,379-21,065-70,500-61,903
Benefit from income taxes-7-6-4-2,198
Net loss-34,372-21,059-70,496-59,705
Unrealized (loss) gain on available-for-sale investments, net of tax-7669-244-55
Foreign currency translation gain2147
Total other comprehensive (loss) income-7470-240-48
Total comprehensive loss-34,446-20,989-70,736-59,753
Net loss per share -- basic and diluted-0.52-0.4-1.22-1.14
Weighted-average common shares outstanding, basic and diluted66,229,34552,993,23857,696,58452,322,523

Balance Sheet

September 30, 2026 — (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents19,99437,983
Marketable securities, current82,56674,960
Prepaid expenses and other current assets2,3342,284
Total current assets104,894115,227
Property and equipment, net131237
Marketable securities, noncurrent5,955
Right-of-use assets133801
Other assets291297
Total assets111,404116,562
Current liabilities:
Accounts payable1,6383,155
Accrued expenses8,9137,857
Operating lease liabilities, current138403
Total current liabilities10,68911,415
Operating lease liabilities, noncurrent435
Warrant liability43,607
Total liabilities54,29611,850
Stockholders’ equity:
Additional paid-in capital574,214551,082
Accumulated deficit-516,950-446,454
Accumulated other comprehensive (loss) income-15684
Total stockholders’ equity57,108104,712
Total liabilities and stockholders’ equity111,404116,562

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-70,496-59,705
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense4,5394,559
Change in fair value of warrant liability12,781
Offering costs allocated to warrant liability2,344
Depreciation81100
Accretion of discounts on marketable securities-1,200-2,258
Non-cash lease income-8-7
Loss on sales and disposals of fixed assets, net2437
Gain on lease termination-24
Other, net4-15
Change in operating assets and liabilities:
Prepaid expenses and other assets-243,005
Accounts payable-1,517-3,180
Accrued expenses1,0561,076
Net cash used in operating activities-52,440-56,388
Cash flows from investing activities:
Purchases of property and equipment-14
Proceeds from sale of property and equipment131
Purchases of marketable securities-78,568-67,162
Maturities of marketable securities65,966118,873
Net cash (used) provided by investing activities-12,60151,728
Cash flows from financing activities:
Proceeds from issuance of common stock, Pre-Funded Warrants and Common Stock Warrants50,765
Offering costs-3,860
Proceeds from the exercise of stock options and common stock issued under the 2020 EIP143113
Net cash provided by financing activities47,048113

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option as a monotherapy, expectations regarding timing, enrollment status and success of the Phase 2 portion of the current clinical trial for rezatapopt and filing of a New Drug Application (NDA) for platinum-resistant/refractory ovarian cancer, and the timing and expectations with respect to our projected cash runway. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities, including the successful filing of NDAs, and planned clinical trials, the Company’s ability to execute on its strategy and operate as a clinical stage company, the potential for clinical trials of rezatapopt or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, maintenance by the Company of the FDA’s grant of Orphan Drug Designation status and related benefits for rezatapopt, the Company’s ability to fund operations, and the impact that a global pandemic, other public health emergencies or geopolitical tensions or conflicts may have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, and its other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

PMV Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share amounts)

PMV Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share amounts)

Contacts

Investors Contact:

Tim Smith

Senior Vice President, Head of Corporate Development and Investor Relations investors@pmvpharma.com

Media Contact:

Kathy Vincent

Greig Communications kathy@greigcommunications.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.